RA Capital Management EWTX Position
Active11-Fund ConvergenceRA Capital Management held their position in Edgewise Therapeutics, Inc. (EWTX) in Q4 2025, holding $258.8M worth of shares across 10,428,437 shares.
The position was first reported in Q2 2024 and has been tracked across 7 quarterly 13F filings.
EWTX is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for EDG-7500 in 77 days (Jun 30, 2026), making the timing of RA Capital's position particularly relevant.
Short interest stands at 10.3% of float with 10.5 days to cover, indicating significant bearish positioning against RA Capital's long thesis.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Full company profile →Short Interest
10.3%
10.5 days to cover
RA Capital Management EWTX Position History
Frequently Asked Questions
Does RA Capital Management own EWTX?
Yes. As of Q4 2025, RA Capital Management holds 10,428,437 shares of Edgewise Therapeutics, Inc. (EWTX) valued at $258.8M. This data comes from their SEC 13F filing.
How many hedge funds own EWTX?
11 specialist biotech hedge funds currently hold EWTX, including OrbiMed Advisors, Baker Bros. Advisors, Perceptive Advisors and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy EWTX?
RA Capital Management's position in EWTX was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's EWTX position increasing or decreasing?
RA Capital Management held their EWTX position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
EWTXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →